SRPT Stock Recent News
SRPT LATEST HEADLINES
Sarepta Therapeutics (SRPT) shares soared in premarket trading Friday, a day after the Food and Drug Administration (FDA) allowed expanded use of the biotech's treatment for a rare muscle disease in children, which especially affects boys.
Sarepeta Therapeutics Inc.'s stock soared 38% in premarket trade Friday, after the biotech said the U.S. regulator has approved an expanded indication of its treatment for the rare muscle disorder Duchenne muscular dystrophy.
The biopharmaceutical company says the drug was approved for ambulatory and non-ambulatory people, who are at least 4 years old, and with a confirmed mutation in the DMD gene.
Thursday, the FDA approved labeled indication for Sarepta Therapeutics Inc's SRPT Elevidys (delandistrogene moxeparvovec-rokl) to include individuals with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are at least 4 years of age.
Sarepta Therapeutics shares surged about 36% in premarket trading on Friday as an expanded use approval opened up a bigger market in the U.S. for its gene therapy for patients with Duchenne muscular dystrophy (DMD).
Sarepta Therapeutics (NASDAQ: SRPT), a pharmaceutical company that describes itself as specializing in “precision genetic medicine for rare diseases”, saw its stock price shoot up by 36% in after-hours trading last night. But why? Ground-breaking medical breakthrough Toward the end of the trading day yesterday, Sarepta announced that it had obtained approval from the U.S.
Sarepta rocketed late Thursday after the FDA approved its Duchenne muscular dystrophy gene therapy for all patients age 4 and older.
Sarepta Therapeutics Inc (NASDAQ: SRPT) rallied a whopping 40% in extended hours today following a key announcement from the U.S. Food and Drug Administration regarding Elevidys. Elevidys is the company's treatment for Duchenne muscular dystrophy.
The U.S. Food and Drug Administration allowed the expanded use of Sarepta Therapeutics' gene therapy for all patients with Duchenne muscular dystrophy aged four and above on Thursday.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics announces the expanded U.S. FDA approval of ELEVIDYS to Duchenne muscular dystrophy patients ages 4 and above.